Avalon Globocare Corp. (ALBT) Stock Price & Analysis
Avalon Globocare Corp. (ALBT) rose 4.69% to USD 0.36 as of June 10, 2026 at 02:18 UTC, according to Nexqual real-time market data.
ALBT last closed at USD 0.34; the session ranged USD 0.34–0.37 on volume of 326,587 shares. Market capitalization is $4.30M, with a 52-week range of USD 0.21–4.74 (NCM). Source: Nexqual, June 10, 2026 at 02:18 UTC.
Key Statistics (as of June 10, 2026 at 02:18 UTC)
| Price | USD 0.36 |
|---|---|
| Change | ▲ 4.69% (up) |
| Previous Close | USD 0.34 |
| Open | USD 0.34 |
| Day Range | USD 0.34 – 0.37 |
| 52-Week Range | USD 0.21 – 4.74 |
| Volume | 326,587 shares |
| Market Cap | $4.30M |
| Exchange | NCM |
Technical Analysis (ALBT)
Nexqual's technical model rates ALBT "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:18 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.81 (neutral) |
| vs SMA50 | Below (USD 0.41) |
| MACD | -0.02 (negative) |
Analyst Ratings (ALBT)
Wall Street analysts rate ALBT "None", per Nexqual as of June 10, 2026 at 02:18 UTC.
| Consensus Rating | None |
|---|
Earnings (ALBT)
Source: Nexqual, June 10, 2026 at 02:18 UTC.
Financials & Fundamentals (ALBT)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -501.20% |
| Debt / Equity | 12.1 |
| Current Ratio | 0.38 |
| Total Cash | $775,995 |
| Total Debt | $1.42M |
| Free Cash Flow | $-1.59M |
Source: Nexqual, June 10, 2026 at 02:18 UTC.
Financial Health Score (ALBT)
Nexqual rates Avalon Globocare Corp.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:18 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $776K cash vs $1M debt |
| Cash Flow | Weak — Operating cash flow -$6M |
| Efficiency | Critical — ROE -501%, ROA -39.7% |
Ownership (ALBT)
| Insider Ownership | +7.20% |
|---|---|
| Institutional Ownership | +4.59% |
| Shares Outstanding | 12.05M |
| Float | 9.51M |
| Short % of Float | +1.99% |
Source: Nexqual, June 10, 2026 at 02:18 UTC.
Leadership (ALBT)
Avalon Globocare Corp. is led by Meng Li (age 47), Interim CEO, COO & Secretary, per Nexqual as of June 10, 2026 at 02:18 UTC.
| Interim CEO, COO & Secretary | Meng Li (age 47) |
|---|---|
| Chief Strategy Officer | Luisa Ingargiola (age 57) |
| Chief Financial Officer | Samuel J. Knipper (age 30) |
Major Backers & Investors (ALBT)
Notable institutional backers of Avalon Globocare Corp. include Equitable Holdings, Inc., Fidelity, Citadel, according to Nexqual as of June 10, 2026 at 02:18 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Equitable Holdings, Inc. | 0.5% |
| Fidelity | 0.5% |
| Citadel | 0.47% |
| HRT Financial LP | 0.34% |
| Scientech Research LLC | 0.34% |
| Morgan Stanley | 0.23% |
| Stonex Group Inc. | 0.17% |
| Procyon Advisors, LLC | 0.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.11% |
| Geode Capital | 0.51% |
Source: Nexqual, June 10, 2026 at 02:18 UTC.
From Avalon Globocare Corp.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Avalon GloboCare Corp., together with its subsidiaries, develops innovative artificial intelligence platforms in the United States and China.
- It operates through Consumer Health Technology and Artificial Intelligence Content Technology Segment.
- The company offers automated video generation, enterprise documentation, and workflow automation solutions, as well as cellular therapy and generative AI publishing and software.
- It also distributes the KetoAir device, which is a breathalyzer system that detects acetone levels in exhaled breath; and the AI Nutritionist software program that helps users monitor and manage ketogenic diet and related programs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TRNR | Interactive Strength Inc. | USD 0.7 | ▼ 6.21% |
| MGRX | Mangoceuticals, Inc. | USD 0.34 | ▼ 4.48% |
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.39 | ▼ 2.11% |
| FMTOF | Femto Technologies Inc. | USD 0.68 | ▼ 23.38% |
| CMND | Clearmind Medicine Inc. | USD 3.39 | ▼ 14.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:18 UTC. This page is informational and not investment advice.